Cancer Research Sees Major Boost as New Breakthroughs Emerge From Key Oncology Players
Unmissable investment strategy! The Federal Reserve officially enters a new era of interest rate cuts, these 6 industries have the most profitable potential.
Prepare yourself for the interest rate cut cycle.
6-K: Explanatory Note
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
Express News | Novartis AG CEO Vas Narasimhan: The company has not been involved in the feverish weight loss drug field.
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
Weight Loss Drug Pricing Under Fire With Pills on the Horizon
Express News | The CEO of Novartis said that Novartis will not join the weight loss drug craze.
Express News | Roche: Kisqali approved by the US FDA for the treatment of HR+/HER2- early-stage breast cancer
Novartis Announced New Data From ALITHIOS Open-label Extension Study, Showing First-line Kesimpta (Ofatumumab) Treatment For Up To Six Years Led To Less Disability And Disease Progression In Recently Diagnosed And Treatment-naïve Relapsing Multiple...
Goldman Sachs Remains a Hold on Novartis AG (NOVN)
Novartis AG: Hold Rating Justified Amid Kisqali's Market Potential and FDA Approval
Novartis Kisqali Gains Early Breast Cancer Indication
FDA Approves Novartis Kisqali To Reduce Risk Of Recurrence In People With HR+/HER2- Early Breast Cancer
Major breakthrough in cancer treatment? Pharmaceutical companies invest billions of dollars, competing to bet on targeted radiation therapy.
Radioactive drugs have the potential to become a significant breakthrough in cancer treatment. In the past year, global pharmaceutical giants such as bristol-myers squibb, astrazeneca, and eli lilly and co have invested approximately 10 billion US dollars to actively enter the field of radioactive drugs through acquisitions and collaborations, aiming to replicate the success of Novartis in the drugs Lutathera and Pluvicto. Currently, these radioactive drugs are mainly used to treat certain types of neuroendocrine tumors and prostate cancer, with the potential to expand to the treatment of more types of cancer in the future.
Liquidia Says United Therapeutics' Interference Found by US Court to Have Caused Losses of Over $137 Million
In An Updated Analysis From Phase 3 NATALEE Trial Of Novartis' Kisqali (Ribociclib) Added To Endocrine Therapy Shows Deepening Benefit Beyond Three-year Treatment Period, Reducing Risk Of Recurrence By 28.5%, Compared To ET Alone, For Stage II And III...
J&J Leads H1 Healthcare Deals as Big Pharma Dealmaking Returns: Report
Buy Rating Affirmed: Novartis AG's Strong Growth Outlook and Underestimated Pipeline Potential
Express News | Novartis' innovative drug Tuo Ruida has issued the first batch of prescriptions nationwide.